Private Management Group Decreased By $420,280 Its Hartford Finl Svcs Group (HIG) Stake; Esperion Therapeutics Has 1.33 Sentiment

April 17, 2018 - By Richard Conner

The Hartford Financial Services Group, Inc. (NYSE:HIG) Logo

Private Management Group Inc decreased Hartford Finl Svcs Group Inc (HIG) stake by 4.15% reported in 2017Q4 SEC filing. Private Management Group Inc sold 7,505 shares as Hartford Finl Svcs Group Inc (HIG)’s stock declined 7.99%. The Private Management Group Inc holds 173,124 shares with $9.74M value, down from 180,629 last quarter. Hartford Finl Svcs Group Inc now has $18.78 billion valuation. It closed at $52.04 lastly. It is down 7.71% since April 17, 2017 and is uptrending. It has underperformed by 3.84% the S&P500.

Esperion Therapeutics Inc (ESPR) investors sentiment decreased to 1.33 in Q4 2017. It’s down -0.34, from 1.67 in 2017Q3. The ratio fall, as 77 investment professionals increased or started new equity positions, while 58 sold and reduced stakes in Esperion Therapeutics Inc. The investment professionals in our database now have: 22.69 million shares, down from 22.73 million shares in 2017Q3. Also, the number of investment professionals holding Esperion Therapeutics Inc in top ten equity positions increased from 3 to 6 for an increase of 3. Sold All: 19 Reduced: 39 Increased: 44 New Position: 33.

Investors sentiment decreased to 0.74 in Q4 2017. Its down 0.09, from 0.83 in 2017Q3. It turned negative, as 43 investors sold HIG shares while 216 reduced holdings. 50 funds opened positions while 142 raised stakes. 305.90 million shares or 1.47% less from 310.47 million shares in 2017Q3 were reported. Old Mutual Invsts (Uk) Ltd has 375,040 shares. Macquarie Grp Incorporated Ltd has invested 0% in The Hartford Financial Services Group, Inc. (NYSE:HIG). Sei Invests invested in 0.03% or 162,189 shares. Tdam Usa Incorporated owns 0.01% invested in The Hartford Financial Services Group, Inc. (NYSE:HIG) for 3,678 shares. Moreover, Asset has 0.08% invested in The Hartford Financial Services Group, Inc. (NYSE:HIG) for 10,213 shares. Grantham Mayo Van Otterloo Company Limited Liability Corp holds 0.06% of its portfolio in The Hartford Financial Services Group, Inc. (NYSE:HIG) for 186,175 shares. Whittier Tru Of Nevada stated it has 0.01% in The Hartford Financial Services Group, Inc. (NYSE:HIG). Pillar Pacific Cap Mgmt Lc owns 6,525 shares or 0.04% of their US portfolio. Hudock Grp Limited Liability stated it has 0.01% of its portfolio in The Hartford Financial Services Group, Inc. (NYSE:HIG). Utd Svcs Automobile Association holds 130,786 shares or 0.02% of its portfolio. Lourd Ltd Liability accumulated 5,729 shares. Nuwave Invest Mgmt Ltd Com holds 0.07% of its portfolio in The Hartford Financial Services Group, Inc. (NYSE:HIG) for 1,000 shares. Los Angeles Capital And Equity Rech reported 192,432 shares stake. Wells Fargo And Mn owns 1.76M shares. Franklin owns 8.88M shares or 0.24% of their US portfolio.

Since March 5, 2018, it had 0 insider purchases, and 4 insider sales for $5.27 million activity. Another trade for 11,247 shares valued at $618,585 was made by Gervasi Martha on Friday, March 9. 868 shares valued at $44,607 were sold by Robinson David C on Monday, March 5. 2,319 The Hartford Financial Services Group, Inc. (NYSE:HIG) shares with value of $124,925 were sold by Lewis Scott R.. The insider ELLIOT DOUGLAS G sold $4.48 million.

Private Management Group Inc increased Scripps Networks Interact In (NYSE:SNI) stake by 19,898 shares to 254,037 valued at $21.69 million in 2017Q4. It also upped Green Plains Inc (NASDAQ:GPRE) stake by 181,206 shares and now owns 1.14 million shares. Kcap Finl Inc (NASDAQ:KCAP) was raised too.

Analysts await The Hartford Financial Services Group, Inc. (NYSE:HIG) to report earnings on April, 26 after the close. They expect $1.10 earnings per share, up 10.00% or $0.10 from last year’s $1 per share. HIG’s profit will be $397.03 million for 11.83 P/E if the $1.10 EPS becomes a reality. After $0.81 actual earnings per share reported by The Hartford Financial Services Group, Inc. for the previous quarter, Wall Street now forecasts 35.80% EPS growth.

Among 18 analysts covering Hartford Financial (NYSE:HIG), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Hartford Financial had 50 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Citigroup given on Tuesday, April 10. The rating was maintained by UBS on Wednesday, August 19 with “Buy”. The stock of The Hartford Financial Services Group, Inc. (NYSE:HIG) earned “Buy” rating by Keefe Bruyette & Woods on Wednesday, June 14. The rating was maintained by FBR Capital on Thursday, February 8 with “Hold”. Keefe Bruyette & Woods maintained the shares of HIG in report on Thursday, November 2 with “Buy” rating. The firm earned “Hold” rating on Wednesday, November 18 by Argus Research. The firm has “Hold” rating by Zacks given on Tuesday, September 1. The firm has “Outperform” rating by Credit Suisse given on Tuesday, December 19. The stock has “Market Perform” rating by Wells Fargo on Tuesday, May 17. The rating was downgraded by Atlantic Securities on Wednesday, August 10 to “Neutral”.

Ratings analysis reveals 0 of Esperion Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Esperion Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ESPR was included in 2 notes of analysts from November 14, 2016. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Neutral” rating given on Monday, November 14 by Citigroup. On Thursday, February 23 the stock rating was maintained by RBC Capital Markets with “Sector Perform”.

The stock increased 1.29% or $0.96 during the last trading session, reaching $75.45. About 87,425 shares traded. Esperion Therapeutics, Inc. (ESPR) has risen 89.86% since April 17, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $2.00 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: